PTH and Hypocalcemia: A case of severe symptomatic hypocalcemia related to Nilotinib was also reported, with an immune-mediated destruction of the parathyroid glands or a drug interference with calcium sensing receptors (CaSRs) and ensuing insufficient PTH secretion being the suggested pathogenic mechanisms (113).